BiomX PHGE
NYSE PHGE
$1.67 +0.12 (+7.74%)
As of: Sep 9, 2026 · 3:59 PM EDT

BiomX (PHGE) Total Non-Current Liabilities (2018 - 2026)

BiomX's (PHGE) quarterly Total Non-Current Liabilities came in at $383000.0 in Q2 2026, down 96.97% year-over-year from $12.6 million in Q2 2025, and down 77.27% quarter-over-quarter from $1.7 million in Q1 2026.

Analysis

BiomX (PHGE) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends

BiomX has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $383000.0 for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities fell 96.97% year-over-year to $383000.0; the TTM figure through Jun 2026 stood at $383000.0 (down 96.97% YoY), while the FY2025 annual figure was $706000.0, down 93.47% from the prior year.
  • Total Non-Current Liabilities came in at $383000.0 for Q2 2026 at BiomX, down from $1.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $33.9 million in Q2 2024 to a low of $383000.0 in Q2 2026.
  • Average Total Non-Current Liabilities over 5 years is $13.1 million, with a median of $13.1 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities surged 261.51% in 2022 and slumped 96.97% in 2026.
  • Over 5 years, Total Non-Current Liabilities stood at $16.6 million in 2022, then tumbled by 34.92% to $10.8 million in 2023, then increased by 0.43% to $10.8 million in 2024, then sank by 93.47% to $706000.0 in 2025, then tumbled by 45.75% to $383000.0 in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $383000.0 in Q2 2026, $1.7 million in Q1 2026, and $706000.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 40.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 4.20 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 12.42 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 1.17 Bn
10 BiomX 1.55 Mn 7.73 Mn 97,000.00 383,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 383,000.00
Mar 31, 2026 1.69 Mn
Dec 31, 2025 706,000.00
Sep 30, 2025 10.46 Mn
Jun 30, 2025 12.63 Mn
Mar 31, 2025 14.13 Mn
Dec 31, 2024 10.82 Mn
Sep 30, 2024 13.14 Mn
Jun 30, 2024 33.89 Mn
Dec 31, 2023 10.77 Mn
Sep 30, 2023 12.12 Mn
Jun 30, 2023 13.72 Mn
Mar 31, 2023 15.06 Mn
Dec 31, 2022 16.55 Mn
Sep 30, 2022 17.86 Mn
Jun 30, 2022 19.15 Mn
Mar 31, 2022 18.88 Mn
Dec 31, 2021 19.41 Mn
Sep 30, 2021 19.37 Mn
Jun 30, 2021 5.30 Mn